Profound Medical Inc.

A Profoundly Different Approach to Prostate Cancer Treatment

Profound Medical winner of

MaRS Healthkick 2014
This year, approximately 500,000 men worldwide will be diagnosed with prostate cancer

Many fear the cure more than the disease itself

Though advances in early detection and treatment have dramatically improved survival rates for those diagnosed with prostate cancer, the side-effects commonly associated with current treatments can severely undermine quality of life for its survivors. Loss of healthy bladder, bowel, and erectile function are often part of the treatment outcome, along with fear of recurrence and long recovery periods.

Many men choose the Active Surveillance (otherwise known as 'wait and see') approach when diagnosed with prostate cancer rather than risk this outcome. Unfortunately, some cancers demonstrate aggressive growth, making active surveillance an uneasy and unsatisfactory choice for men anxious about their prostate health and mortality.

Accurate and Minimally Invasive

An Approach to Treatment that is Profoundly Different

Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland. Profound’s novel technology combines Magnetic Resonance Imaging (MRI) technology with ultrasound thermal energy that is delivered via a trans-urethral approach. This method of prostate cancer therapy provides highly accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials.
Profound Technology

Accurate, Effective, Minimally Invasive
The Profound Solution
Arguably the best medical imaging tool in common use today, Magnetic Resonance Imaging (MRI) enables a clinician to “see” in detail the internal organs of a patient non-invasively while thermal coagulation therapy has proven utility in multiple medical treatment applications.

When combining the two methodologies, the opportunity exists for an optimal and vastly superior clinical outcome. Profound has developed a novel MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the regions of the prostate gland via a trans-urethral approach. Featuring intelligent closed-loop control via real-time thermal imaging, the Profound system offers unparalleled accuracy.

The system has been extensively tested and delivered consistent and predictable proof-of-concept results in mathematical, gel, pre-clinical models and the technology is approved for Safety and Feasibility Clinical trials in North America and Europe, currently enrolling patients.

System Features

Safety & compatibility within an MRI suite

Accurate location of the trans-urethral ultrasound applicator in the prostate

Customisable 3D treatment planning options through proprietary software

Precise heating control through unique array geometries and frequencies

Whole or segmented treatments relative to disease progression and location

Single treatment, within MR scanner, on outpatient basis

Real-time thermometry for active monitoring and surveillance

Control around critical organs such as nerve bundles, rectum & bladder
Management Team

Steven Plymale

CEO

Mr. Plymale has over two decades of senior management experience in the medical device industry and was most recently the Vice President and General Manager of Xltek, a division of Natus Medical Incorporated. Prior to this appointment, Mr. Plymale served in various senior management roles in a number of notable medical device companies. Bringing to bear a unique blend of management skills and experience, his focus on Operations, Quality & Regulatory Affairs and Strategic Planning is a distinct asset to Profound Medical and the numberous Boards to which he contributes his time and expertise.

Shameze Rampertab

CFO

Shameze Rampertab has more than 15 years of life sciences public company and capital markets experience. He was most recently Vice-President, Finance and Chief Financial Officer at Intellipharmaceutics International Inc. and also served as Chairman and Director of Imaging Dynamics Company Limited. Prior to this he was a Partner in Healthcare Investment Banking at Loewen, Ondaatje, McCutcheon Limited. He also served as Health Sciences and Biotechnology Analyst at several investment banking firms such as Jennings Capital Inc., Canaccord Capital Corporation and Sprott Inc. Previously he served as the Director, Finance and Secretary-Treasurer for Drug Royalty Inc. Mr. Rampertab has substantial expertise with financing, licensing and royalty deals.

Ronald Kurtz, M.Eng.

VP-Engineering

Mr. Kurtz has two decades of experience in Engineering management and design, primarily focused on medical device development. Prior to joining Profound, Mr. Kurtz served as Vice-President of Research and Development at Xltek, successfully developing, patenting and commercializing a broad portfolio of diagnostic neurology products, benefiting the company's 2006 IPO and subsequent sale to Natus. Mr. Kurtz holds a Masters of Engineering degree from McGill University and possesses deep expertise in all aspects of product lifecycle management, including formal clinical studies, regulatory approvals and market launches.

Goldy Singh

VP-Quality & Regulatory Affairs

Ms. Singh has been in the medical device industry for over two decades and has secured 510K and CE-mark approvals on a range of complex devices, leading both Quality and Regulatory Affairs for a number of companies, including C.R. Bard and Philips Medical. Most recently as Director of Quality & Regulatory Affairs at Natus Medical Incorporated, she managed a large product portfolio through a series of successfully launched products into the US, Canada and EU. A reviewer of RAPS online university course material, Ms. Singh is also regularly invited to share her unique expertise at industry and peer-attended events.
Profound Board of Directors

Profound Medical Inc. receives guidance and governance from a Board of Directors that embodies deep experience in the medical device industry and a strong history of success

Jean-François Pariseau M.Sc., MBA, Partner, Health Venture Fund, BDC Venture Capital

Jean-François Pariseau joined BDC Venture Capital in July 2001. He has over 17 years of investment and entrepreneurial experience in the life sciences sector. He has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Jean-Francois’ experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, he was CEO of a consulting company specializing in regulatory affairs as well as VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC-Montréal. He currently sits on the Board of Directors of AngioChem Inc., Osprey Pharmaceuticals USA, Profound Medical Inc. and BioQuébec.

Damian Lamb, Genesys Capital Partners Co-Founder and Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $200 million in venture capital funds, and has been involved in deploying over $90 million in 18 investments. He currently serves on the Board of Affinium Pharmaceuticals Inc.. He has served on the Board of Ionalytics Corporation (recently sold to Thermo Electron Corp.), Millenium Biologix and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Steven Plymale, CEO, Profound Medical Inc.
Mr. Plymale has over two decades of senior management experience in the medical device industry and was most recently the Vice President and General Manager of Xltek, a division of Natus Medical Incorporated. Xltek, formerly a public company, was acquired by Natus Medical in November 2007, and designs, manufactures and sells a broad portfolio of diagnostic monitoring devices for Neurology. Prior to this appointment Mr. Plymale served in various senior management roles within several medical device companies (such as ISG Technologices,/Cedara Software, CryoCath Technology, Claron Technology and The Bluehaven Consulting group). Mr. Plymale brings a unique blend of management skills and experience focusing on Operations, Quality & Regulatory Affairs and Strategic Planning.

William E. Curran

Mr. Curran has extensive experience in operations, finance and executive management. He was formerly President and Chief Executive Officer of Philips Electronics North America. He served in diverse functional and senior management positions during his career with Philips, including as Chief Operating Officer of Philips Medical Systems North America. Mr. Curran currently serves on the Board of 3D Systems (NYSE: DDD) and is Chairman of the Audit Committee and a member of the Executive Committee. He was non-executive Chairman and a Director of Resonant Medical before it was sold to Elekta A.B. in 2010.He has previously served as a director for companies in the medical, electronics, and software industries.

Arun Menawat, President and CEO, Novadaq Technologies Inc.

Arun Menawat has been Novadaq Technologies Inc.’s President and Chief Executive Officer since April 2003. Previously, he held senior management positions at Cedara Software, Tenneco, Inc. and Hercules, Inc. His educational background includes a Bachelor of Science in Biology, University of District of Columbia, Washington, District of Columbia, and a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and a Fellowship in Biomedical Engineering from the National Institute of Health, Bethesda, MD. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.
Clinical Advisory Board

Profound Medical's research and clinical trials are further informed by the considerable collective expertise of well-experienced clinicians, specializing in urology and radiology

Peter Albertsen, Chief and Program Director of the Division of Urology, Professor of Surgery, University of Connecticut Health Center

Scott Eggener, Co-Director, Prostate Cancer Program Director, Translational and Outcomes Research, Section of Urology, Associate Professor of Surgery, University of Chicago

Adam Kibel, Chief of Urology, Brigham and Women's Hospital Chief of Urology, Dana-Farber Cancer Institute, Professor of Surgery, Harvard Medical School, Dana-Farber/Harvard Cancer Center

Eric Klein, Chairman of the Glickman Urological and Kidney Institute, Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic

Laurence Klotz, Chief of Urology, Sunnybrook Health Sciences Center, Professor of Surgery, University of Toronto

Aytekin Oto, Chief of Body MRI, Section Chief of Abdominal Imaging, Professor of Radiology, University of Chicago

Ian Thompson, Glenda and Gary Woods Distinguished Chair in GU Oncology, Professor, Department of Urology, University of Texas Health Science Center, San Antonio
Careers at Profound

As Profound Medical Inc. progresses in the development program of its minimally invasive treatment for prostate cancer, we will continue to seek qualified, committed professionals to join our team.

We are committed to fostering an inclusive, accessible environment where all employees feel respected and supported. We are dedicated to building a diverse workforce and creating an environment where every employee has the opportunity to reach his/her full potential.
Software Developer - 1 Year Contract

Profound Medical Inc. is seeking an experienced Medical Device Software Developer who has extensive experience working in C# and C++ , for a 1 year contract assignment.

We are a young, creative and passionate organization committed to making a difference in men’s health with our unique treatment for prostate cancer ablation. As part of a diverse and high performing engineering team, you will be joining the organization at an exciting time as we move towards commercialization. You will play an important role in a supportive, collaborative and fast-paced environment. The successful applicant will be a friendly and outgoing team player, results focused with a “can do” attitude and able to work autonomously.

If you are interested in knowing more about the position requirements and job responsibilities, please read full details here: Software Developer Job Description

Those individuals who meet the requirements for this contract position and are interested in applying should submit their resume and cover letter to: hr@profoundmedical.com

Compensation is commensurate with experience.
Information for Prospective Investors

Profound Medical was launched in Toronto, Canada, in 2008. We are a clinical stage company, focused on building a truly unique product and brand presence.

We are a well-funded company, but sensibly, are always interested in hearing from potential financing partners. Should you be interested in discussing investment opportunities at Profound Medical, please contact us.
Latest News

Mira IV Acquisition Corp. announces proposed Qualifying Transaction with Profound Medical Inc.

Profound News Release

Profound Medical appoints

Dr. Arun Menawat

to Board of Directors

Profound News Release

Profound Medical appoints

Shameze Rampertab

as Chief Financial Officer

Profound News Release

Profound Medical receives IDE approval from FDA to conduct TULSA clinical trial

for new treatment

for localized

prostate cancer

Profound News Release

Clinical trial first

for less invasive procedure to treat prostate cancer

DAVID ANDREATTA
The Globe and Mail

World first in

prostate cancer treatment at LHSC

CTV London

Profound Medical announces initiation

of TULSA clinical trial for treatment

of localized

prostate cancer

Profound News Release

New minimally invasive prostate cancer treatment offers hope to patients

CancerCareNews.ca

November 2014

Visit

Profound Medical

at these

2015 Conferences

EUA, March 20 - 24

Bloom Burton & Co. Healthcare

Investor Conference, May 4 - 5

AUA, May 15 - 19
We Welcome All Enquiries

Your interest in Profound Medical is appreciated and we invite you to contact us in the following ways

647.476.1350

3080 Yonge Street,

Suite 4040, Box 34
Toronto, ON
M4N 3N1

info@profoundmedical.com
CONTACT US

If you would prefer to contact us through this website, please complete the following form and we will respond as soon as we are able.

Name
Please enter a name.

Email
Invalid email.

Message

Comment

Thanks for your message!